Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease (Q38809361)

6 September 2017

title

Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease (English)

1 reference

6 September 2017

0 references

0 references

0 references

0 references

Robert B Laprairie

1

1 reference

6 September 2017

Amina M Bagher

series ordinal

2

1 reference

6 September 2017

Melanie E M Kelly

series ordinal

3

1 reference

6 September 2017

Eileen M Denovan-Wright

series ordinal

4

1 reference

6 September 2017

publication date

23 December 2015

1 reference

6 September 2017

published in

Molecular Pharmacology

1 reference

6 September 2017

volume

89

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

364-375

1 reference

Co-expression of the human cannabinoid receptor coding region splice variants (hCB₁) affects the function of hCB₁ receptor complexes

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

A restricted population of CB1 cannabinoid receptors with neuroprotective activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Advances in G protein-coupled receptor allostery: from function to structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Controlled clinical trial of cannabidiol in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Evolution of the content of THC and other major cannabinoids in drug-type cannabis cuttings and seedlings during growth of plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Functional studies cast light on receptor states

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

The endocannabinoid system as a target for the treatment of motor dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

A simple method for quantifying functional selectivity and agonist bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

CNR1 variation is associated with the age at onset in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through CA2 -dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Huntington's disease: an update of therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cholera toxin impairment of opioid-mediated inhibition of adenylate cyclase in neuroblastoma × glioma hybrid cells is due to a toxin-induced decrease in opioid receptor levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Worsening of Huntington disease phenotype in CB1 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cholera toxin treatment produces down-regulation of the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Agonistic properties of cannabidiol at 5-HT1a receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

The orphan receptor GPR55 is a novel cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Effect of chronic administration of R-( )-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

Emerging paradigms in GPCR allostery: implications for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1124/MOL.115.101980

21 January 2018

Identifiers

DOI

10.1124/MOL.115.101980

1 reference

6 September 2017

1 reference